PRDS Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Pardes Biosciences, Inc

Pardes Biosciences Announces Closing of Tender Offer

2 years ago - By: Foresite Capital

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

2 years ago - By: MediPacific, Inc.

MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

2 years ago - By: Benzinga

Why Pardes Biosciences Shares Are Rising Monday

2 years ago - By: Benzinga

Recap: Pardes Biosciences Q1 Earnings

2 years ago - By: Kahn Swick & Foti, LLC

PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS

3 years ago - By: RM LAW, P.C.

RM LAW Announces Investigation of Pardes Biosciences, Inc.

2 years ago - By: Brodsky & Smith LLC - Mentions: SCU NLTX AJX RITM

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sculptor Capital Management Inc. (NYSE – SCU), Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Great Ajax Corp. (NYSE – AJX)

2 years ago - By: Kahn Swick & Foti, LLC

PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS

2 years ago - By: The Schall Law Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

2 years ago - By: Brodsky & Smith LLC - Mentions: NLTX KLR AJX

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Kaleyra, Inc. (NYSE – KLR), Great Ajax Corp. (NYSE – AJX)

2 years ago - By: Halper Sadeh LLC

PRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to Shareholders

2 years ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether Pardes Biosciences, Inc. has obtained a Fair Price in its transaction with MediPacific

2 years ago - By: Seeking Alpha

Pardes Biosciences soars after co to be acquired by MediPacific (NASDAQ:PRDS)

2 years ago - By: Pardes Biosciences, Inc

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

2 years ago - By: Pardes Biosciences, Inc

Pardes Biosciences Reports First Quarter 2023 Financial Results

3 years ago - By: InvestorPlace - Mentions: TMPO SFR ZVSA NXPL ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

3 years ago - By: Seeking Alpha

Pardes stock falls after COVID drug trial failure prompts strategic review

3 years ago - By: Pardes Biosciences, Inc

Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

3 years ago - By: Pardes Biosciences, Inc

PARDES BIOSCIENCES INC (PRDS) Stock News

PRDS Latest News, Press Relases and Analysis

Pardes Biosciences Announces Closing of Tender Offer

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

Why Pardes Biosciences Shares Are Rising Monday

Recap: Pardes Biosciences Q1 Earnings

PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS

RM LAW Announces Investigation of Pardes Biosciences, Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sculptor Capital Management Inc. (NYSE – SCU), Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Great Ajax Corp. (NYSE – AJX)

PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Kaleyra, Inc. (NYSE – KLR), Great Ajax Corp. (NYSE – AJX)

PRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to Shareholders

Shareholder Alert: Ademi LLP investigates whether Pardes Biosciences, Inc. has obtained a Fair Price in its transaction with MediPacific

Pardes Biosciences soars after co to be acquired by MediPacific (NASDAQ:PRDS)

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

Pardes Biosciences Reports First Quarter 2023 Financial Results

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pardes stock falls after COVID drug trial failure prompts strategic review

Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Pardes Biosciences to Present at SVB Securities Global Biopharma Conference